Objective: To investigate the changes in plasma lipids and lipoproteins, low-density lipopro tein (LDL) oxidizability, and plasma homocysteine during postmenopausal sequential 3-monthly hormone replacement therapy.
being investigated to reduce the frequency and se verity of the bleeding episodes, thereby improving patient compliance.
Until now, cardiovascular consequences of such alternative hormone therapies have not been pub lished. Reducing the frequency of progestogen ad ministration may reduce the reported adverse effect of progestogens on the lipid profile (8) and therefore be beneficial with respect to the cardiovascular risk. However, it may also increase the risk of developing endometrial hyperplasia (6, 7). Therefore, this alter native HRT regimen needs more research before it can be considered for general use.
To approximate the influence of HRT regimen with respect to the risk of developing cardiovascular disease (CVD) it is common practice to study the changes in plasma lipids and lipoproteins, However, these changes only partly contribute to the preven tive effects of HRT on CVD risk in postmenopausal women (9) .
New risk estimators of great interest are the size of low-density lipoprotein (LDL) particles and their susceptibility to oxidation in vitro. It has been re ported that small LDL particles (10) as well as oxi dized LDL particles (11) have greater atherogenic properties than native LDL. Furthermore, small LDL particles are more susceptible to oxidation (12) . For LDL oxidation three parameters are relevant (13): [1] the lag time, [2] the oxidation rate, and [3] the maximal amount of dienes produced at the end of the final oxidation. The lag time is the time needed to obtain a significant increase in lipid peroxidation products (dienes) and is considered a function of the amount of antioxidants present in the LDL. The rate at which lipid peroxidation occurs is another rele vant parameter of LDL oxidizability. Finally, lipid peroxidation stops because of the lack of substrate: the total amount of dienes produced is the third rele vant parameter of LDL oxidizability. Exogenous hor mones may influence LDL oxidizability (14) .
Homocysteine has been found to be another im portant risk factor for CVD independent of plasma lipid profiles (15) . Its reported increase after meno pause has been suggested to explain part of the in creased risk of developing CVD in postmenopausal women (16) . The recently published data on de creased homocysteine levels during HRT (17) may indeed partially account for the decreased risk in CVD during postmenopausal HRT.
This study was designed to investigate the effects of 3-monthly progestogen administration during es trogen supplementation as an alternative for the usually practiced monthly administration. This arti cle reports the effects of this regimen on plasma lip ids and lipoproteins, parameters of LDL oxidizabil ity, and plasma homocysteine.
Patients
This study was approved by the Institutional Re view Board of the University Hospital Nijmegen. The participating women were recruited by adver tisement in a local newspaper. Selected subjects were healthy postmenopausal nonhysterectomized women aged 45 to 60 years who gave their written informed consent on beforehand. They were amenorrhoic for at least 6 months and their serum FSH concentrations were higher than 36 mlU/mL (con version factor to SI unit, 1.00). No estrogen or pro gestogen therapy was used within 90 days before screening. Excluded were women with a history or active presence of any contraindication for HRT. In addition, also excluded were women with a systolic blood pressure higher than 160 mm Hg and diastolic blood pressure higher than 100 mm Hg, an endocrine disease except for controlled thyroid disease, and to tal cholesterol concentrations higher than 7.5 mmol/ L. Women with any malignancy except for succesfully resected basal cell skin cancer, malabsorbtion disorders, obesity (exceeding 20% of ideal range for weight and height), a smoking habit, alcohol or drug abuse, or malignant changes on the prestudy mam mogram were not included. Furthermore, use of lipid-lowering agents, dopaminergic or antidopaminergic drugs, niacin, clonidine, and tibolone within 30 days of the screening was not permitted. None of the women reported supplementation of vitamins re lated to homocysteine metabolism, such as vitamin B6, Bi2 and folate supplements.
Beside medical history, the screening consisted of physical and gynecologic examination, including Pa panicolaou smear and endometrial biopsy by micro curettage (Endocurette; Farina Lanfranco, Venezia, Italy), mammography (unless performed within 6 months before screening), routine laboratory hema tology, blood chemistry, and urinalysis determina tions. Furthermore, FSH and lipid and lipoproteins were assayed. At baseline, i.e., between 7 and 21 days after screening, the lipid and lipoproteins were quantified again to assess possible fluctuations in time. Also, plasma samples were taken for homocys teine assays and then the study treatment was started. Baseline values were used in calculations and shown in Tables 1 to 4. On cycle days 82 through 84 of the 84-day cycles two and four, the endometrial biopsy was repeated and blood samples were drawn for determination of lipids, lipoproteins, and homo cysteine. At cycle four the Papanicolaou smear, the mammography, routine laboratory hematology, blood chemistry, and urinalysis were repeated.
After screening, 41 women were included. One woman was considered a screening failure because
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Lipids and Lipoproteins
Very low-density lipoproteins were isolated from plasma within 5 days after blood sampling by ultra centrifugation at d = 1.006 g/mL using a Kontron TFT 45.6 rotor for 16 hours at 168,000 X g at 14°C in a Beckman L 7-55 ultracentrifuge (Beckman In struments, Inc., Palo Alto, CA). High-density lipo protein cholesterol (HDL-C) in stored plasma sam ples was determined weekly by the polyethylene glycol 6000 method. For HDL-C the interassay coef ficient of variation (CV) amounted to 2.3% (n = 20). Plasma total cholesterol and triglycerides (TG) were measured by enzymatic methods using commercially available reagents (CHOD-PAP cholesterol reagent, cat. no. 237574; Boehringer Mannheim, Mannheim, Germany, and SERA-PAK TG cat. no. 6684; Miles, Milan, Italy). Both measurements were performed with a centrifugal analyzer (Multistat III; Instru mentation Laboratory, Lexington, MA). Interassay CVs were 1.7% and 1.5%, respectively (n = 20). The accuracy check for cholesterol against an Abell-Kendall method approved by the Centers for Disease Control (CDC; Atlanta, GA) was within 3% of target values. Low-density lipoprotein cholesterol (LDL-C) was calculated by subtracting the cholesterol con tent in the d < 1.006 g/mL fraction and in the HDL fraction from total plasma cholesterol. Plasma sam ples used for apolipoproteins and total homocysteine determinations were stored at -80°C until the end of the study. To minimize the imprecision all sam ples from the same subject were analyzed in dupli cate in the same run. Apolipoprotein (Apo) A-I and B were measured by immunonephelometry; accuracy was adjusted to CDC criteria on the base of an ex change of sera.
Low-Density Lipoprotein Isolation and In Vitro Oxidation
Plasma was separated from the blood within 1 to 2 hours and aliquots were stored at ~80°C in the presence of 6 g saccharose/L. To minimize analytical variation, all samples of the same subject were ana lyzed in the same run. Low-density lipoproteins were isolated by a short-run ultracentrifugation method and were thereafter tested for their susceptibility to copper-induced LDL oxidation in vitro (18) . Briefly, after isolation and washing by subsequent ultracen trifugation for 16 hours at 168,000 X g , the LDL was dialyzed for 24 hours in the dark at 4°C against phosphate-buffered saline (pH 7.4), containing 10 /¿mol/L EDTA. The buffer was made oxygen-free by vacuum degassing, followed by purging with nitro gen. The LDL-containing sample was filtered through a 0.45-//m filter and diluted with dialysis buffer to a final concentration of 0.05 mg LDL-protein/mL and 10 /imol EDTA/L. The oxidation was initiated by the addition of a freshly prepared solu tion (15 /¿mol/L) of copper chloride (CuCl2). The ki netics of LDL oxidation were determined by monitor ing the change in the 234-nm diene absorbtion on an UV-spectrophotometer (Lambda 5; Perkin-Elmer, Norwalk, CT), equipped with a six-position au tomatic sample changer, at 30°C. The change of ab sorbance at 234-nm versus time was divided into three consecutive phases, i.e., a lag phase, a propa gation phase, and a decomposition phase. Oxidation parameters (lag time, maximal rate of oxidation, and total amount of conjugated dienes formed during oxi dation) were calculated as described previously (18) .
Fatty Acids in LD L
The LDL samples (0.4 mL) were saponified by in cubation with 1.6 mL of 0.3 mol NaOH/L in 90% ethanol (vol/vol) at 37°C for 1 hour. To 0.4 mL of the mixture, 0.4 mL of water and 50 ¡jL of 12 mol HCl/ L was added. The fatty acids were extracted twice with 2 mL n-hexane. The pooled organic phase was evaporated to dryness under a stream of nitrogen. The residue was dissolved in 100 jllL of ethanol containing 400 ¡ jlmol/L of heptadecanoic acid as an internal standard and derivatized to 4-nitrophenylhydrazides as described elsewhere (19 
of nitrogen at room tem perature. This procedure was repeated twice. The residue was dis solved in 800 ¡Új of absolute methanol, and a 2-//L aliquot was analyzed for fatty acids by high-perfor mance liquid chromatography (HPLC; Spectra Phys ics, Eindhoven, The Netherlands). A ChromSep col um n packed w ith Chromspher C8 (20 X 100 mm; Chrompack, Middelburg, the N etherlands) was used to elute the fatty acids with 80% (vol/vol) acetonitrile (pH adjusted to 4.5 with sulfuric acid) at a flow rate of 0.25 mL/min. The absorbance at 390 nm was m easured with a Spectra Physics (SP 8450) spec trophotom eter (Spectra Physics, Eindhoven, the Netherlands). For technical reasons the fatty acid m easurem ent in LDL both at baseline and cycle two was performed in only 27 women.
Vitamin E
The vitam in E concentrations in LDL were deter mined by HPLC as described previously (12), For technical reasons the vitam in E m easurem ent both at baseline and cycle two was performed in only 19 women.
Homocysteine
Total homocysteine was m easured in plasma, stored at -80°C until the end of the study, by HPLC followed by fluorimetrie detection according to Fiskerstrand et al. with some modifications (20) . The de tection lim it was 0,5 ¿¿mol/L and the intra-and in terassay coefficient of variation am ounted both to < 5 % .
Statistics
Unless indicated statistical "endpoint analyses" were performed on data of 39 women, of whom a t least data at cycle two were available, using the "last visit carried forward" procedure. All statistical com parisons were performed with the Friedm an twoway analysis of variance, and the Wilcoxon's signedrank test, A P value < 0.05 was considered to be statistically significant. Statistical analyses were performed with the Dyna-stat computer program (Dynamic Microsystems, Inc., Washington, D.C.).
RESULTS
Study Population
C haracteristics of the study population are given in Table 1 , D uring the treatm ent period no clinically relevant changes were found in body m ass index and blood pressure.
Lipids and (Apo) lip opro teins
F asting plasm a concentrations of lipids and lipo proteins a t baseline and on cycle days 82 through 84 of cycles two and four are given in Table 2 . Between screening and baseline no significant differences were detected in the plasm a lipids and lipoproteins, except for a 10,1% difference (P = 0.04) in th e triglyc erides (screening: 1.19 ± 0.56 mmol/L; baseline: 1,07 ± 0.37 mmol/L). Compared w ith baseline values, to tal cholesterol and LDL-C were 3.5% (P < 0.05) and 8.7% (P < 0.01) lower, respectively, w hereas HDL-C and TG were 6.5% (P < 0.05) and 16% (P < 0 ,01) higher, respectively. P arallel to HDL-C, Apo A-I was 9.0% (P < 0 .0001) higher, w hereas Apo B rem ained unchanged. Furtherm ore, th e atherogenic indices LDL-C/HDL-C and Apo B/Apo A-I were 13% (P < 0.001) and 11% (P < 0.0001) lower, respectively.
LDL Oxidation
The LDL oxidation characteristics showed minor changes after two cycles of tre a tm e n t (6 months): lag tim e decreased from 109 ± 24 to 105 ± 22 m in utes (m ean ± SD) (P < 0,05), oxidation ra te de creased from 9.6 ± 1.6 to 9.3 ± 1,7 nmol dienes/m in per m illigram LDL protein (m ean ± SD), and the maximum am ount of produced dienes decreased from 552 ± 65 to 530 ± 59 nmol/mg protein (P < 0.01), Table 3 shows d a ta of fatty acid composition and vitam in E contents in LDL. The percentages of palm itic acid, stearic acid, oleic acid, and linoleic acid, and th e vitam in E concentration changed sig nificantly.
Homocysteine
Fasting plasm a homocysteine was 6.7% lower (P < 0.05) in cycle two, b u t re tu rn e d to baseline level in cycle four (Table 4) . W hen dividing the study pop ulation into women w ith lower plasm a homocysteine cular risk. This could be of great importance consid ering the fact that this alternative HRT regimen was designed to improve compliance, especially for those women in need of long-term treatment to prevent CVD. However, this hypothesis needs further re search by prospective randomized studies, because minor variations in different studies over time in different women do not allow this conclusion to be drawn. Low-density lipoprotein oxidation has been sug gested to be an additional important risk factor for atherogenesis. Once LDL is infiltrated in the vascu lar bed, a supply of antioxidants prevents lipidperoxidation of the polyunsaturated fatty acids within the LDL. Indeed, 17/3-E2 administered by intra-arterial infusion, patch application, or by implantation re duced the lag time of the LDL oxidizability curve (14, 22) . In our study we observed a decrease in the lag time of in vitro oxidation with 3.7%, a significant, but probably not a physiological difference because the ratio of vitamin E per milligram Apo B did not change. Furthermore, oxidation rates remained sim ilar, despite a slight but statistically significant de crease in the relative content of linoleic acid, which is sensitive to oxidation in contrast to palmitic acid or oleic acid.
Inherent to the choice of hormone regimen, changes in plasma lipoproteins as well as in LDL oxidizability are small. Previously, we showed that LDL consists of three subfractions: LDL3 with the highest density was most rapidly oxidized with Cu2+ in vitro (12). On the other hand, the LDL subfraction pattern is a function of plasma TG concentration. So, if a HRT regimen is designed with small changes in plasma lipids and lipoproteins, such as the pres ent one, then changes in LDL oxidizability will be minimal. This indeed could be established.
Possible explanations for the difference with our own findings are the different kinds of estrogens used (17/3-E2 versus conjugated estrogens in our study), the route of administration (intra-arterial, transdermal, implantation versus oral administra tion in our study), and the duration of administra tion (direct, 3 and 16 weeks versus 6 months in our study), and possibly most important the administra tion of a progestogen. Progestogens reportedly coun teract the beneficial effects of estrogen administra tion on lipid profiles (8),
Homocysteine is an independent risk factor for CVD (15) . It was demonstrated that plasma homo cysteine concentrations in postmenopausal women are higher than in premenopausal women and there fore may contribute to the increased cardiovascular risk in postmenopausal women (16) . Furthermore, postmenopausal E2/dydrogesterone administration for 2 years was associated with a decrease in serum homocysteine, which may contribute to the cardio protective effect of HRT (17) . The recently reported observation by Anker et al. (23) adds to this conclu sion. They found a reduction in plasma homocysteine of 29.8% after 9 to 12 months and of 24.5% after 13 to 18 months of treatment with the anti-estrogen tamoxifen, a adjuvant drug that has been associated with reduced cardiovascular mortality, which is given to women with breast cancer. Our present ob servation during 12 months of conjugated estrogenmedrogestone administration, however, indicates that the reduction in homocysteine may only be tem porary. In relation to previous studies we used a relative high dosage of medrogestone, possibly ex erting an unfavorable effect on homocysteine metab olism. In agreement with previous observations (17), the decreases in homocysteine, if any, were espe cially observed in those women having higher homo cysteine concentrations, indicating that they may benefit the most of the homocysteine-lowering in fluence of HRT.
Arterioclerotic changes related to elevated homo cysteine concentrations have been suggested to be induced by increased lipid peroxidation due to reac tive oxygen generation by homocysteine (24). Blom et al. (25) failed to confirm this hypothesis in in vitro oxidation studies in hyperhomocysteinemic subjects. In the present study LDL oxidation showed a small but significant increase, not in line with the tempo rarily decreased homocysteine concentrations.
From the data obtained in this study, it can be concluded that this sequential HRT regimen induced several favorable changes in lipid and lipoprotein concentrations, as well as in homocysteine concen trations, which may counteract the minor undesir able changes in LDL susceptibility to oxidation. Therefore, our data explain in part the reduced risk of developing CVD in postmenopausal women on HRT.
